18 Jul 17

BioSante Pharmaceuticals first-one fourth net loss boosts to $10.5 million BioSante Pharmaceuticals, Inc cialis tadalafil 20mg india . today reported on its latest developments and financial outcomes for the first one fourth, and its own cash balance by March 31, 2010. Latest BioSante Developments Closed $18 million Registered Immediate Financing: BioSante added around $18 million to its cash balance due to its March 2010 authorized direct offering, getting its March 31, 2010 cash stability to around $41.2 million. The LibiGel safety research continues, with no adjustments, based on the wonderful security profile observed to time.

professional consultation online

BioScale announces outcomes of two pharmacodynamic biomarkers using assay AMMP technology BioScale Inc. The info presented in this article show obviously that the BioScale system presents a robust and speedy way for measuring recombinant criteria or endogenously derived proteins from both cells tradition and mouse xenograft tumor lysates. Zhong-Hua Yan, Senior Scientist at Millennium Pharmaceuticals: The Takeda Oncology Firm, was the lead writer of this article. Dr. Michael Bembenek, Associate Director, Lead Discovery, oversaw the comparative analyses which were performed in the scholarly research. For this extensive study, pharmacodynamic biomarkers for both proteasome and phosphoinositol 3-kinase inhibition were utilized.